Why Did Glucotrack Stock Surge 12% Pre-Market Today?

• The patents issued cover critical aspects of Glucotrack’s implantable CBGM technology.
• Unlike conventional CGM systems that sample glucose from interstitial fluid, Glucotrack’s device measures glucose directly from blood.
• The long-term, fully implantable design offers more convenient option for diabetes management.

Glucotrack, Inc. (GCTK) announced on Thursday that it has secured three new U.S. patents for its continuous blood glucose monitoring (CBGM) platform. 

The patents are expected to boost the company’s intellectual property portfolio as it moves its long-term implantable monitoring system closer to commercialization.

Following the update, Glucotrack stock traded over 12% higher in Thursday’s premarket. 

New Patents Strengthen IP

The US Patent and Trademark Office issued Patent Nos. US 12,453,494, US 12,458,257, and US 12,458,258, covering critical aspects of Glucotrack’s implantable CBGM technology.

The patents protect innovations in sensor chemistry, intravascular lead design, and low-power electronics, all integral to the company’s implantable system.

On Stocktwits, retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day and message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours. 

Clinical And Practical Significance

Unlike conventional CGM systems that sample glucose from interstitial fluid, Glucotrack’s device measures glucose directly from blood. This approach is expected to provide near real-time readings, eliminating the lag commonly seen with subcutaneous sensors. 

“Securing our intellectual property is fundamental to our strategy as we advance our fully implantable, long-term sensor through further clinical testing and toward commercialization.”

-Paul V. Goode, President and CEO, Glucotrack

The long-term, fully implantable design also aims to reduce patient burden and improve adherence, offering a potentially more convenient option for diabetes management.

Glucotrack’s CBGM is a fully implantable device that tracks blood sugar continuously for up to three years. It does not require any wearable parts on the body and needs very little calibration. 

GCTK stock has declined by over 97% in the last 12 months. 

Also See: Why Did GUTS Stock Plummet Today Despite Positive Gut Therapy Midterm Study?

For updates and corrections, email newsroom[at]stocktwits[dot]com.

Share

·

Add us on